CYP19A1 and breast carcinoma: Only one of these STS inhibitors (Irosustat) has reached clinical trials (phase II) showing clinical benefits when combined with an aromatase inhibitor, but larger studies are required before to be translating this to a marketed drug to treat breast cancer [21,22,23].